Korea / Special Situations, Clepsydra Capital

Sanghyun Park

Korea / Special Situations

Korea / Special Sits, Pairs, Index Rebalancing

Clepsydra Capital

Investigate special situations, pairs, and index rebalancing trades in Korea.

Event-Driven

<ul>
<li>The swap prices, ₩148,853 for Celltrion Inc and ₩66,874 for Celltrion Healthcare, specified below are not tentative prices but confirmed prices. So, the merger ratio has been determined as 1:0.4492620.</li>
<li>The key focus now is the appraisal rights exercise. Both offer attractive spreads. Yet, the ₩1T combined ceiling might seem restricted considering potential dissenting Celltrion Inc shareholders exceeding expectations.</li>
<li>Nonetheless, considering the strong determination of the company towards this merger, we should consider a strategy of approaching this spread aggressively while keeping the cancellation risk in mind.</li>
</ul>


The swap prices, ₩148,853 for Celltrion Inc and ₩66,874 for Celltrion Healthcare, specified below are not tentative prices but confirmed prices. So, the merger ratio has been determined as 1:0.4492620.
The key focus now is the appraisal rights exercise. Both offer attractive spreads. Yet, the ₩1T combined ceiling might seem restricted considering potential dissenting Celltrion Inc shareholders exceeding expectations.
Nonetheless, considering the strong determination of the company towards this merger, we should consider a strategy of approaching this spread aggressively while keeping the cancellation risk in mind.


Celltrion Merger Swap: Conditions & Schedule

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hk-inno-n-corp" target="_blank" data-smartkarma-citation="entities:33522:1" rel="noopener">HK inno.N (195940 KS)</a> recorded impressive sequential improvement in 2Q23 result, while YoY comparison is negatively impacted by high base due to one-off cervical cancer vaccine revenue recorded in 2Q22.</li>
<li>In 2Q23, revenue increased 11% QoQ to KRW204B and operating profit grew 172% QoQ to KRW15B. Growth was mainly driven by a 19% QoQ growth in K-CAB domestic revenue.</li>
<li>HK inno targets KRW1T K-CAB revenue by entering 100 countries globally by 2028. The company is adding new growth engines such as IV fluids products, MSD vaccine, and biosimilars.</li>
</ul>



HK inno.N (195940 KS) recorded impressive sequential improvement in 2Q23 result, while YoY comparison is negatively impacted by high base due to one-off cervical cancer vaccine revenue recorded in 2Q22.
In 2Q23, revenue increased 11% QoQ to KRW204B and operating profit grew 172% QoQ to KRW15B. Growth was mainly driven by a 19% QoQ growth in K-CAB domestic revenue.
HK inno targets KRW1T K-CAB revenue by entering 100 countries globally by 2028. The company is adding new growth engines such as IV fluids products, MSD vaccine, and biosimilars.


HK Inno.N (195940 KS): 2Q23 Result Shows Strong Sequential Improvement; K-CAB Continues to Fly High

Quantitative Researcher, MRM Research

Nico Rosti

Quantitative Researcher

MRM Research

Quantitative Research

Equity Derivatives

Korea Stock Exchange KOSPI 200 / Equity Derivatives

<ul>
<li>The <a href="https://www.smartkarma.com/entities/korea-stock-exchange-kospi-200" target="_blank" data-smartkarma-citation="entities:26021:1" rel="noopener">KOSPI 200 (KOSPI2 INDEX EQUITY)</a> last week closed the week down (CC=-1) after a strong rise the previous week. Could be getting ready to rise higher.
</li>
<li>The index last week tested supports in the Market Reversal Matrix's Q2/Median support area (around 335).</li>
<li>
Valid support levels for the coming week (if CC=-2) are between 333 (Q2) and 324 (Q3).</li>
</ul>


The KOSPI 200 (KOSPI2 INDEX EQUITY) last week closed the week down (CC=-1) after a strong rise the previous week. Could be getting ready to rise higher.

The index last week tested supports in the Market Reversal Matrix's Q2/Median support area (around 335).

Valid support levels for the coming week (if CC=-2) are between 333 (Q2) and 324 (Q3).


EQD | KOSPI 200 Index WEEKLY: Rising After a Brief Pullback

<ul>
<li>Yonhap News reported on the exclusive coverage of Ecopro BM and L&amp;F's KOSPI transfer listing.</li>
<li>L&amp;F announced through the disclosure that they are considering the KOSPI transfer listing. Ecopro BM told another local news outlet that they are not currently reviewing the KOSPI transfer listing.</li>
<li>It seems that L&amp;F's KOSPI transfer listing is almost a confirmed fact. However, the Ecopro company in question may be Ecopro Co, not Ecopro BM.</li>
</ul>


Yonhap News reported on the exclusive coverage of Ecopro BM and L&amp;F's KOSPI transfer listing.
L&amp;F announced through the disclosure that they are considering the KOSPI transfer listing. Ecopro BM told another local news outlet that they are not currently reviewing the KOSPI transfer listing.
It seems that L&amp;F's KOSPI transfer listing is almost a confirmed fact. However, the Ecopro company in question may be Ecopro Co, not Ecopro BM.


What We Know Until Now About L&F & Ecopro BM's Kospi Transfer Listing

<ul>
<li>A previously published <a href="https://www.smartkarma.com/insights/eqd-kospi-200-index-weekly-time-to-go-long" target="_blank" rel="noopener">insight</a> correctly highlighted an high-probability opportunity to go LONG and join the <a href="https://www.smartkarma.com/entities/korea-stock-exchange-kospi-200" target="_blank" data-smartkarma-citation="entities:26021:1" rel="noopener">KOSPI 200</a>'s current multi-month Bull run.</li>
<li>The index closed the week strongly up, now we want to evaluate how far this new leg up could go: a total of +3/+4 weeks up, price targets =359-385.</li>
<li>Holders of KOSPI 200 LONG positions: Covered Calls can be written at Strikes between 346 and 360, expiry August 10th (4 weeks). A pullback is highly probable from 360.
</li>
</ul>


A previously published insight correctly highlighted an high-probability opportunity to go LONG and join the KOSPI 200's current multi-month Bull run.
The index closed the week strongly up, now we want to evaluate how far this new leg up could go: a total of +3/+4 weeks up, price targets =359-385.
Holders of KOSPI 200 LONG positions: Covered Calls can be written at Strikes between 346 and 360, expiry August 10th (4 weeks). A pullback is highly probable from 360.



EQD | KOSPI 200 Index WEEKLY Rising: How Far Can It Go?

South Korea

Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies.  The Company's main product is Abata cept which is for arthritis treatment

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Celltrion Inc (068270 KS)

Celltrion Merger Swap: Conditions & Schedule

This post details the Celltrion merger swap event, announced just now after the market closed. It provides detailed conditions and schedules along...

Sanghyun Park

HK Inno.N (195940 KS): 2Q23 Result Shows Strong Sequential Improvement; K-CAB Continues to Fly High

In 2Q23, revenue increased 11% QoQ and operating profit grew 172% QoQ. K-CAB domestic revenue grew 19% QoQ. Flagship drug, K-CAB has been launched...

Tina Banerjee

EQD | KOSPI 200 Index WEEKLY: Rising After a Brief Pullback

The KOSPI 200 Index's may be preparing for a new rally, this pullback may be just a buy-the-dip opportunity, check the latest Market Reversal...

Nico Rosti

What We Know Until Now About L&F & Ecopro BM's Kospi Transfer Listing

This post provides the latest update on today's news about the possibility of L&F and Ecopro BM's KOSPI transfer listing.

Sanghyun Park

EQD | KOSPI 200 Index WEEKLY Rising: How Far Can It Go?

Market Reversal Matrix (MRM)'s analysis of the KOSPI 200's WEEKLY current uptrend: price levels where the trend can stop and probability of...

Nico Rosti

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)